{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:26:49Z","timestamp":1793406409927,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T00:00:00Z","timestamp":1397174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s10875-014-0024-5","type":"journal-article","created":{"date-parts":[[2014,4,10]],"date-time":"2014-04-10T04:19:43Z","timestamp":1397103583000},"page":"120-126","source":"Crossref","is-referenced-by-count":42,"title":["Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations"],"prefix":"10.1007","volume":"34","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"24_CR1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","volume":"126","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC. Intravenous immunoglobulin therapy for neurological diseases. Ann Intern Med. 1997;126:721\u201330.","journal-title":"Ann Intern Med"},{"key":"24_CR2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","volume":"22","author":"MC Dalakas","year":"1999","unstructured":"Dalakas MC. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. Muscle Nerve. 1999;22:1479\u201397.","journal-title":"Muscle Nerve"},{"key":"24_CR3","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291:2367\u201375.","journal-title":"JAMA"},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"MC Dalakas","year":"2004","unstructured":"Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neurological disorders: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177\u201393.","journal-title":"Pharmacol Ther"},{"key":"24_CR5","volume-title":"Fifth international symposium of IVIg","year":"2004","unstructured":"Dalakas MC, Spath PJ, editors. Fifth international symposium of IVIg. UK: Parthenon Publishers; 2004."},{"key":"24_CR6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-065X.1994.tb00858.x","volume":"139","author":"MD Kazatchkine","year":"1994","unstructured":"Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin. Immunol Rev. 1994;139:79\u2013107.","journal-title":"Immunol Rev"},{"key":"24_CR7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","volume":"345","author":"MD Kazatchkine","year":"2001","unstructured":"Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345:747\u201355.","journal-title":"N Engl J Med"},{"key":"24_CR8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.4049\/jimmunol.144.4.1387","volume":"144","author":"KH Roux","year":"1990","unstructured":"Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype\u2013anti-idiotype dimers in pooled human IgG. J Immunol. 1990;144:1387\u201392.","journal-title":"J Immunol"},{"key":"24_CR9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410390121","volume":"39","author":"U Malik","year":"1996","unstructured":"Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous y-globulin inhibits binding of anti-GMI to its target antigen. Ann Neurol. 1996;39:136\u20139.","journal-title":"Ann Neurol"},{"key":"24_CR10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","volume":"51","author":"B Buchwald","year":"2002","unstructured":"Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barr\u00e9 syndrome. Ann Neurol. 2002;51:673\u201380.","journal-title":"Ann Neurol"},{"key":"24_CR11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ana.10259","volume":"51","author":"MC Dalakas","year":"2002","unstructured":"Dalakas MC. Blockade of blocking antibodies in Guillain-Barr\u00e9 syndromes: \u201cunblocking\u201d the mystery of action of intravenous immunoglobulin. Ann Neurol. 2002;51:667\u20139.","journal-title":"Ann Neurol"},{"key":"24_CR12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"MC Dalakas","year":"2001","unstructured":"Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy BS. High-dose intravenous immunoglobulin for Stiff-Person Syndrome. N Engl J Med. 2001;345:1870\u20136.","journal-title":"N Engl J Med"},{"key":"24_CR13","doi-asserted-by":"crossref","unstructured":"Fouka P, Alexopoulos H, Politis P, Dalakas MC. Investigating the effector function of IVIg in Stiff Person Syndrome. Neurology. 2014 (in press).","DOI":"10.1016\/B978-0-12-385157-4.00646-1"},{"key":"24_CR14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.expneurol.2013.02.010","volume":"247","author":"MC Dalakas","year":"2013","unstructured":"Dalakas MC. Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. Exp Neurol. 2013;247:303\u20137.","journal-title":"Exp Neurol"},{"issue":"11","key":"24_CR15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1586\/1744666X.2013.845527","volume":"9","author":"H Alexopoulos","year":"2013","unstructured":"Alexopoulos H, Dalakas MC. Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Rev Clin Immunol. 2013;9(11):1043\u201353.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1\u20132","key":"24_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jneuroim.2007.11.020","volume":"194","author":"S Fuchs","year":"2008","unstructured":"Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, et al. A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol. 2008;194(1\u20132):89\u201396.","journal-title":"J Neuroimmunol"},{"key":"24_CR17","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487\u201398.","journal-title":"N Engl J Med"},{"key":"24_CR18","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immunoglobulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993\u20132000.","journal-title":"N Engl J Med"},{"key":"24_CR19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","volume":"94","author":"M Basta","year":"1994","unstructured":"Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729\u201335.","journal-title":"J Clin Invest"},{"key":"24_CR20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/brain\/awh127","volume":"127","author":"G Zhang","year":"2004","unstructured":"Zhang G, Lopez PH, Li CY, Mehta NR, Griffin JW, Schnaar RL, et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain. 2004;127:1085\u2013100.","journal-title":"Brain"},{"key":"24_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","volume":"139","author":"N Yuki","year":"1996","unstructured":"Yuki N, Miyaga F. Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies. J Neurol Sci. 1996;139:160\u20132.","journal-title":"J Neurol Sci"},{"issue":"1","key":"24_CR22","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1136\/jnnp.2010.205856","volume":"82","author":"N Yuki","year":"2011","unstructured":"Yuki N, Watanabe H, Nakajima T, Sp\u00e4th PJ. IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motorneuropathy. Neurol Neurosurg Psychiatry. 2011;82(1):87\u201391.","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"24_CR23","unstructured":"L\u00fcnemann JD, Nimmerjahn F, Dalakas MC. Induction of immunoglobulin G Fc-sialylation is associated with disease remission in CIDP. J Clinical Immunol. 2014 (in press)."},{"issue":"Suppl 1","key":"24_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1529-8027.2011.00305.x","volume":"16","author":"F Nimmerjahn","year":"2011","unstructured":"Nimmerjahn F, L\u00fcnemann JD. Expression and function of the inhibitory Fc\u03b3-receptor in CIDP. Peripher Nerv Syst. 2011;16 Suppl 1:41\u20134.","journal-title":"Peripher Nerv Syst"},{"issue":"3","key":"24_CR25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0b013e31827debad","volume":"80","author":"AK Mausberg","year":"2013","unstructured":"Mausberg AK, Dorok M, Stettner M, M\u00fcller M, Hartung HP, Dehmel T, et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology. 2013;80(3):296\u2013303.","journal-title":"Neurology"},{"key":"24_CR26","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1073\/pnas.89.8.3325","volume":"89","author":"JJ Marchalonis","year":"1992","unstructured":"Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T cell receptor V\u03b2 chain. Proc Natl Acad Sci U S A. 1992;89:3325\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24_CR27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"K Amemiya","year":"2000","unstructured":"Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-\u03b21 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol. 2000;94:99\u2013104.","journal-title":"Clin Immunol"},{"key":"24_CR28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-065X.1994.tb00854.x","volume":"139","author":"Y Abe","year":"1994","unstructured":"Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev. 1994;139:5\u201319.","journal-title":"Immunol Rev"},{"key":"24_CR29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1365-2249.1999.00757.x","volume":"115","author":"P Ankrust","year":"1999","unstructured":"Ankrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Froland SS. Administration of intravenous immunoglobulin (IVIg) in vivo downregulatory effects on the IL-1 system. Clin Exp Immunol. 1999;115:136\u201343.","journal-title":"Clin Exp Immunol"},{"key":"24_CR30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1212\/WNL.54.1.65","volume":"54","author":"Y Choi","year":"2000","unstructured":"Choi Y, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with Inflammatory Myopathies. Neurology. 2000;54:65\u201371.","journal-title":"Neurology"},{"key":"24_CR31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-5728(02)00430-7","volume":"135","author":"A Creange","year":"2003","unstructured":"Creange A, Gregson NA, Hughes RA. Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FCgammaRII expression in patients with chronic inflammatory neuropathies. J Neuroimmunol. 2003;135:91\u20135.","journal-title":"J Neuroimmunol"},{"key":"24_CR32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.410430404","volume":"43","author":"BC Kieseier","year":"1998","unstructured":"Kieseier BC, Clements JM, Pischel HB, Wells GM, Miller K, Gearing AJ, et al. MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barre syndrome. Ann Neurol. 1998;43:427\u201334.","journal-title":"Ann Neurol"},{"key":"24_CR33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/clin.1994.1091","volume":"71","author":"D Rigal","year":"1994","unstructured":"Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effect of IVIg in peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effect on LFA-1 and CD56 molecules. Clin Immunol Immunopathol. 1994;71:309\u201314.","journal-title":"Clin Immunol Immunopathol"},{"key":"24_CR34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1212\/WNL.52.9.1833","volume":"52","author":"MK Sharief","year":"1999","unstructured":"Sharief MK, Ingram DA, Swash M, Thompson EJ. I.V. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barre syndrome. Neurology. 1999;52:1833\u20138.","journal-title":"Neurology"},{"key":"24_CR35","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"R Raju","year":"2005","unstructured":"Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biologic validation of clinical relevant genes. Brain. 2005;128:1887\u201396.","journal-title":"Brain"},{"issue":"1\u20132","key":"24_CR36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jneuroim.2004.10.021","volume":"159","author":"S Renaud","year":"2005","unstructured":"Renaud S, Hays AP, Brannagan 3rd TH, Sander HW, Edgar M, Weimer LH, et al. Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol. 2005;159(1\u20132):203\u201314.","journal-title":"J Neuroimmunol"},{"issue":"3","key":"24_CR37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","volume":"48","author":"MC Dalakas","year":"1997","unstructured":"Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo- controlled study. Neurology. 1997;48(3):712\u20136.","journal-title":"Neurology"},{"issue":"8","key":"24_CR38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ncpneuro0261","volume":"2","author":"MC Dalakas","year":"2006","unstructured":"Dalakas MC. Sporadic inclusion body myositis\u2013diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol. 2006;2(8):437\u201347.","journal-title":"Nat Clin Pract Neurol"},{"issue":"8","key":"24_CR39","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/NEN.0b013e31826183c8","volume":"71","author":"V Askanas","year":"2012","unstructured":"Askanas V, Engel WK, Nogalska A. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol. 2012;71(8):680\u201393.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"24_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.21452","volume":"64","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. Interplay between inflammation and degeneration: using inclusion body myositis to study \u201cneuroinflammation\u201d. Ann Neurol. 2008;64(1):1\u20133.","journal-title":"Ann Neurol"},{"issue":"Pt 5","key":"24_CR41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/brain\/awn053","volume":"131","author":"J Schmidt","year":"2008","unstructured":"Schmidt J, Barthel K, Wrede A, Salajegheh M, Bahr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain. 2008;131(Pt 5):1228\u201340.","journal-title":"Brain"},{"issue":"12","key":"24_CR42","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/jnnp.2009.174276","volume":"80","author":"IE Muth","year":"2009","unstructured":"Muth IE, Barthel K, Bahr M, Dalakas MC, Schmidt J. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry. 2009;80(12):1344\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Pt 4","key":"24_CR43","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/brain\/aws046","volume":"135","author":"J Schmidt","year":"2012","unstructured":"Schmidt J, Barthel K, Zschuntzsch J, Muth IE, Swindle EJ, Hombach A, et al. Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of beta-amyloid and cell death. Brain. 2012;135(Pt 4):1102\u201314.","journal-title":"Brain"},{"issue":"11","key":"24_CR44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1586\/1744666X.2013.842467","volume":"9","author":"J Schmidt","year":"2013","unstructured":"Schmidt J. Dalakas MC Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Rev Clin Immunol. 2013;9(11):1125\u201333.","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"24_CR45","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1002\/art.37692","volume":"64","author":"J Zschuntzsch","year":"2012","unstructured":"Zschuntzsch J, Voss J, Creus K, Sehmisch S, Raju R, Dalakas MC, et al. Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and beta-amyloid in the muscle. Arthritis Rheum. 2012;64(12):4094\u2013103.","journal-title":"Arthritis Rheum"},{"key":"24_CR46","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awg235","volume":"126","author":"BC Jacobs","year":"2003","unstructured":"Jacobs BC, O\u2019Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain. 2003;126:2220\u201334.","journal-title":"Brain"},{"key":"24_CR47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.410380214","volume":"38","author":"I Illa","year":"1995","unstructured":"Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillain Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral injection of gangliosides. Ann Neurol. 1995;38:218\u201324.","journal-title":"Ann Neurol"},{"key":"24_CR48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"EA Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259\u201362.","journal-title":"Ann Intern Med"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-014-0024-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-014-0024-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-014-0024-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:44:42Z","timestamp":1689122682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-014-0024-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":48,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["24"],"URL":"https:\/\/doi.org\/10.1007\/s10875-014-0024-5","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]}}}